Systematic review of disease-modifying antirheumatic drugs for juvenile idiopathic arthritis

Systematic review of disease-modifying antirheumatic drugs for juvenile idiopathic arthritis

<p>Abstract</p> <p>Background</p> <p>Treatment of juvenile idiopathic arthritis (JIA) with disease-modifying antirheumatic drugs (DMARDs) may improve outcomes compared to conventional therapy (e.g., non-steroidal anti-inflammatory drugs, intra-articular corticosteroids)...

Full description

Bibliographic Details
Main Authors:	Kemper Alex R, Van Mater Heather A, Coeytaux Remy R, Williams John W, Sanders Gillian D
Format:	Article
Language:	English
Published:	BMC 2012-03-01
Series:	BMC Pediatrics
Subjects:	Juvenile rheumatoid arthritis Disease-modifying antirheumatic drugs Comparative effectiveness research Systematic review
Online Access:	http://www.biomedcentral.com/1471-2431/12/29

Similar Items

Treatment adherence to disease-modifying antirheumatic drugs in Chinese patients with rheumatoid arthritis
by: Xia Y, et al.
Published: (2016-05-01)

Risk of New-Onset Diabetes Mellitus Associated with Antirheumatic Drugs in Patients with Rheumatoid Arthritis: A Nationwide Population Study
by: So Hye Nam, et al.
Published: (2022-04-01)

Factors associated with initial or subsequent choice of biologic disease-modifying antirheumatic drugs for treatment of rheumatoid arthritis
by: Yinzhu Jin, et al.
Published: (2017-07-01)

Comparison of the efficacy and safety of methotrexate alone or in combination with leflunomide in the treatment of juvenile idiopathic arthritis: a double-blind, placebo-controlled, randomized trial
by: Zahra Rezaieyazdi, et al.
Published: (2023-03-01)

Patients With Rheumatoid Arthritis With an Inadequate Response to Disease‐Modifying Antirheumatic Drugs at a Higher Risk of Acute Coronary Syndrome
by: Chung‐Yuan Hsu, et al.
Published: (2021-04-01)

Preferences of patients with rheumatoid arthritis regarding disease-modifying antirheumatic drugs: a discrete choice experiment
by: van Heuckelum M, et al.
Published: (2019-07-01)

The use of biological disease-modifying antirheumatic drugs for inflammatory arthritis in Korea: results of a Korean Expert Consensus
by: Eun-Jung Park, et al.
Published: (2020-01-01)

Effect of biological disease-modifying antirheumatic drugs on body composition in patients with rheumatoid arthritis: a systematic review and meta-analysis
by: Mariana Peixoto Guimarães Ubirajara e Silva de Souza, et al.
Published: (2022-05-01)

The clinical effectiveness and cost-effectiveness of abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis: a systematic review and economic evaluation
by: Jonathan Shepherd, et al.
Published: (2016-04-01)

Treatment patterns in rheumatoid arthritis patients newly initiated on biologic and conventional synthetic disease-modifying antirheumatic drug therapy and enrolled in a North American clinical registry
by: Philip J. Mease, et al.
Published: (2021-09-01)

Dynamics of patient reported outcomes during the use various biological disease-modifying antirheumatic drugs for rheumatoid arthritis
by: A. E. Karateev, et al.
Published: (2022-09-01)

Biologic Disease-Modifying and Other Anti-Rheumatic Drugs Use in Patients with Moderate-to-Severe Juvenile Idiopathic Arthritis Based on a Japanese Nationwide Claims Database
by: Hata T, et al.
Published: (2022-08-01)

Effect of immunomodulating treatment (usage of DMARDs) in rheumatoid arthritis on depression
by: Magdalena Kozyra, et al.
Published: (2020-08-01)

Juvenile idiopathic arthritis
by: Krupa H Bhatt, et al.
Published: (2014-01-01)

Efficacy and safety of progressively reducing biologic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis in persistent remission: a study protocol for a non-inferiority randomized, controlled, single-blind trial
by: Shangwen Lei, et al.
Published: (2022-07-01)

Treatment patterns and economic outcomes in patients with juvenile idiopathic arthritis
by: Marshall A, et al.
Published: (2019-05-01)

Patient access to reimbursed biological disease-modifying antirheumatic drugs in the European region
by: Zoltán Kaló, et al.
Published: (2017-01-01)

Tocilizumab may slow radiographic progression in patients with systemic or polyarticular-course juvenile idiopathic arthritis: post hoc radiographic analysis from two randomized controlled trials
by: Clara Malattia, et al.
Published: (2020-09-01)

The use of biological disease-modifying antirheumatic drugs and Janus kinase inhibitors in rheumatoid arthritis during the COVID-19 coronavirus disease pandemic: data from a telephone survey of 254 patients
by: A. E. Karateev, et al.
Published: (2022-05-01)

Switching and Discontinuation Pattern of Biologic Disease-Modifying Antirheumatic Drugs and Tofacitinib for Patients With Rheumatoid Arthritis in Taiwan
by: Ko-Jen Li, et al.
Published: (2021-07-01)

Seroprevalence of Antibodies against SARS-CoV-2 in Children with Juvenile Idiopathic Arthritis a Case-Control Study
by: Violetta Opoka-Winiarska, et al.
Published: (2021-04-01)

Treatment of juvenile rheumatoid arthritis
by: Kwang Nam Kim
Published: (2010-11-01)

Managing Disease-Modifying Antirheumatic Drugs (DMARDs) for Patients Undergoing Elective Spine Surgery: A Pilot Survey
by: James C. Mamaril-Davis, et al.
Published: (2024-01-01)

Factors influencing prescribing the first add-on disease-modifying antirheumatic drugs in patients initiating methotrexate for rheumatoid arthritis
by: Yinan Huang, et al.
Published: (2023-09-01)

Conventional disease-modifying agents in rheumatoid arthritis – a review of their current use and role in treatment algorithms
by: Ivan Padjen, et al.
Published: (2020-12-01)

Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for the treatment of rheumatoid arthritis not previously treated with disease-modifying antirheumatic drugs and after the failure of conventional disease-modifying antirheumatic drugs only: systematic review and economic evaluation
by: Matt Stevenson, et al.
Published: (2016-04-01)

Early rheumatoid arthritis therapy: comparative characteristic of delagil, sulphasalazine and methotrexate
by: T S Salnikova, et al.
Published: (2003-08-01)

MODERN VIEWS ON PATHOGENETIC THERAPY OF RHEUMATOID ARTHRITIS
by: D. G. Rekalov, et al.
Published: (2013-12-01)

Analysis of juvenile idiopathic arthritis associated uveitis in India over the last 16 years
by: Sudharshan S, et al.
Published: (2007-01-01)

Drug safety analyses in a rheumatoid arthritis registry: application of different approaches regarding timing of exposure and confounder measurement
by: Daniel H. Solomon, et al.
Published: (2017-06-01)

Prospects for rheumatoid arthritis pharmacotherapy: New opportunities and recommendations
by: E L Nasonov
Published: (2016-12-01)

First-year drug therapy of new-onset rheumatoid and undifferentiated arthritis: a nationwide register-based study
by: Paula Muilu, et al.
Published: (2020-07-01)

Ultrasound-detected bone erosion is a relapse risk factor after discontinuation of biologic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis whose ultrasound power Doppler synovitis activity and clinical disease activity are well controlled
by: Shin-ya Kawashiri, et al.
Published: (2017-05-01)

Randomised controlled trial of Tumour necrosis factor inhibitors Against Combination Intensive Therapy with conventional disease-modifying antirheumatic drugs in established rheumatoid arthritis: the TACIT trial and associated systematic reviews
by: David L Scott, et al.
Published: (2014-10-01)

Certolizumab pegol and secukinumab for treating active psoriatic arthritis following inadequate response to disease-modifying antirheumatic drugs: a systematic review and economic evaluation
by: Mark Corbett, et al.
Published: (2017-10-01)

Incident and recurrent herpes zoster for first-line bDMARD and tsDMARD users in seropositive rheumatoid arthritis patients: a nationwide cohort study
by: Seogsong Jeong, et al.
Published: (2022-07-01)

Mangosteen ethanol extract alleviated the severity of collagen-induced arthritis in rats and produced synergistic effects with methotrexate
by: Jian Zuo, et al.
Published: (2018-01-01)

Thyroid Autoimmunity and Function after Treatment with Biological Antirheumatic Agents in Rheumatoid Arthritis
by: Sofie Bliddal, et al.
Published: (2017-07-01)

JUVENILE CHRONIC ARTHRITIS WITH EYE LESION
by: S O Salugina, et al.
Published: (2002-02-01)

Treatment of refractory juvenile idiopathic arthritis via pulse therapy using methylprednisolone and cyclophosphamide
by: Tania Caroline Monteiro de Castro, et al.